Application of electrochemical impedance spectroscopy in sensor systems, devices, and related methods
View Patent ↗A diagnostic Electrochemical Impedance Spectroscopy (EIS) procedure is applied to measure values of impedance-related parameters for one or more sensing electrodes. The parameters may include real impedance, imaginary impedance, impedance magnitude, and/or phase angle. The measured values of the impedance-related parameters are then used in performing sensor diagnostics, calculating a highly-reliable fused sensor glucose value based on signals from a plurality of redundant sensing electrodes, calibrating sensors, detecting interferents within close proximity of one or more sensing electrodes, and testing surface area characteristics of electroplated electrodes. Advantageously, impedance-related parameters can be defined that are substantially glucose-independent over specific ranges of frequencies. An Application Specific Integrated Circuit (ASIC) enables implementation of the EIS-based diagnostics, fusion algorithms, and other processes based on measurement of EIS-based parameters.
1. A glucose sensor system comprising:
a glucose sensor, said sensor having an electrode that is configured to be implanted or subcutaneously disposed in the body of a patient; and
sensor electronics operably coupled to said sensor and being configured to:
periodically perform an electrochemical impedance spectroscopy (EIS) procedure to obtain values of impedance magnitude for said electrode, wherein the electrode is disposed inside an insulin-infusion catheter such that, when insulin is infused, said infused insulin is in close proximity to said electrode within the patient's body;
obtain values of measured current (Isig) for said electrode;
monitor said Isig and said values of impedance magnitude for said electrode over time;
detect a spike in the monitored Isig and determine whether, at about the time of said Isig spike, there is also an increase in the monitored value of the impedance magnitude; and
determine that an interferent exists in close proximity to the electrode i£ at about the time of said spike in Isig, there is also an increase in the monitored values of the impedance magnitude, wherein the interferent is m-cresol.
2. The system of claim 1 , wherein the time interval between consecutive applications of the EIS procedure is determined based on the timing of insulin delivery through said insulin-infusion catheter.
3. The system of claim 1 , wherein said values of impedance magnitude are obtained at a frequency of about 1 kHz.
4. The system of claim 1 , wherein, after said spike, the Isig is no longer responsive to glucose for a period of time thereafter.
5. The system of claim 4 , wherein said period of time is less than one hour.
6. A glucose sensor system comprising:
a glucose sensor, said sensor having an electrode that is configured to be implanted or subcutaneously disposed in the body of a patient; and
sensor electronics operably coupled to said sensor and being configured to:
periodically perform an electrochemical impedance spectroscopy (EIS) procedure to obtain values of impedance magnitude for said electrode, wherein the electrode is disposed inside an insulin-infusion catheter such that, when insulin is infused, said infused insulin is in close proximity to said electrode within the patient's body;
obtain values of measured current (Isig) for said electrode;
monitor said Isig and said values of impedance magnitude for said electrode over time;
detect a spike in the monitored Isig and determine whether, at about the time of said Isig spike, there is also an increase in the monitored value of the impedance magnitude; and
determine that an interferent exists in close proximity to the electrode if, at about the time of said spike in Isig, there is also an increase in the monitored values of the impedance magnitude,
wherein, after said spike, the Isig is no longer responsive to glucose for a period of time thereafter;
wherein the duration of said period of time is dependent upon the rate of diffusion of said interferent through the patient's body; and
wherein the interferent is insulin.
7. The system of claim 6 , wherein the time interval between consecutive applications of the EIS procedure is determined based on the timing of insulin delivery through said insulin-infusion catheter.
8. The system of claim 6 , wherein said values of impedance magnitude are obtained at a frequency of about 1 kHz.
9. The system of claim 6 , wherein said period of time is less than one hour.